Varvello Loris, Arnò Celeste, Coggiola Marisa, Ramassotto Elena, Pascale Claudio
Divisione di Medicina Interna, Ospedale Cottolengo di Torino.
Ann Ital Med Int. 2002 Oct-Dec;17(4):252-5.
The development of cholestasis during treatment with ticlopidine is an uncommon event in view of the large number of patients to whom this drug is prescribed. We describe the cases of 2 patients who had been treated with ticlopidine for 4 weeks and 2 months respectively. The first patient developed cholestasis with jaundice and pruritus while the second presented with biochemical cholestasis but no jaundice. When treatment with ticlopidine was withdrawn, in the first case pruritus disappeared and jaundice improved. In both cases the liver function tests returned to normal. Both patients were treated with ursodeoxycholic acid which might have an anticholestatic effect in case of hepatotoxicity induced by ticlopidine.
鉴于服用噻氯匹定的患者数量众多,治疗期间发生胆汁淤积是一种罕见事件。我们描述了2例分别接受噻氯匹定治疗4周和2个月的患者病例。第一例患者出现胆汁淤积伴黄疸和瘙痒,而第二例表现为生化性胆汁淤积但无黄疸。停用噻氯匹定治疗后,第一例患者的瘙痒消失,黄疸有所改善。两例患者的肝功能检查均恢复正常。两名患者均接受了熊去氧胆酸治疗,在噻氯匹定引起肝毒性的情况下,熊去氧胆酸可能具有抗胆汁淤积作用。